Company intelligence / Profile preview

Autónomo

Rockville, Maryland, United Statesgestoraz.com ↗

Ownership: Private
Development stage: Other

Overview

Autonomous Therapeutics is developing first-in-class nucleic acid-based medicines that are designed to be both target-specific and resistant to viral variants. Their technology aims to provide precision and resistance-proof immunity against diseases such as influenza and metastatic cancers. No clinical results have been published yet; the company appears to be in preclinical development.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Nucleic acid therapyRNA therapy (specifically "Encrypted RNA™" and novel nucleic acids)
Industry: Biotech

Beyond the preview

Go deeper on Autónomo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Autónomo.

Explore the full profile